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PPRECLINICAL STUDY
Scavenging Free Radicals by Low-Dose Carvedilol
Prevents Redox-Dependent Ca2 Leak Via
Stabilization of Ryanodine Receptor in Heart Failure
Mamoru Mochizuki, MD,* Masafumi Yano, MD, PHD,* Tetsuro Oda, MD, PHD,*
Hiroki Tateishi, MD,* Shigeki Kobayashi, MD, PHD,* Takeshi Yamamoto, MD, PHD,*
Yasuhiro Ikeda, MD, PHD,* Tomoko Ohkusa, MD, PHD,* Noriaki Ikemoto, PHD,†‡
Masunori Matsuzaki, MD, PHD, FACC*
Ube, Japan; and Watertown and Boston, Massachusetts
Objectives We investigated whether defective intracellular Ca2 handling is corrected by carvedilol in heart failure.
Background In heart failure, the interaction between the N-terminal and central domains of the ryanodine receptor (RyR), the
domains where many mutations have been found in patients with catecholaminergic polymorphic ventricular
tachycardia (CPVT), is defective, as shown in our recent report.
Methods Sarcoplasmic reticulum vesicles were isolated from canine left ventricular muscle (normal or 4-weeks rapid ven-
tricular pacing). The RyR was labeled with the fluorescent conformational probe methylcoumarin acetate (MCA)
with DPc10 (a synthetic peptide corresponding to Gly2460-Pro2495 of RyR, one of the mutable domains in CPVT)
as a site-direction carrier.
Results Normal cardiac function was well preserved in carvedilol-treated/paced dogs (CV) but not in the untreated/
paced dogs (CV). In CV, the interdomain interaction within RyR was defective (i.e., in an unzipped state), as
determined by the fluorescence quenching technique. However, in CV, the domain interaction remained nor-
mal (i.e., in a zipped state). In CV, oxidative stress of RyR (reduction in the number of free thiols) was se-
vere, but it was negligible in CV. In (CV) failing cardiomyocytes, incubation with low-dose CV (30 nmol/l),
which eliminated intracellular reactive oxygen species with no acute effect on cell shortening, markedly im-
proved the contractile function and Ca2 transient. However, after domain unzipping by DPc10, CV was
without effect.
Conclusions Carvedilol, at a concentration that is sufficient to produce antioxidant effect, improves the intracellular Ca2
handling and contractile dysfunction by correcting defective interdomain interaction within the RyR in the failing
heart. (J Am Coll Cardiol 2007;49:1722–32) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.064d
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ihe interaction between 2 specific domains (N-terminal:
esidue 1-600 and central: 2000-2500 domains), where
any reported malignant hyperthermia (MH) and central
ore disease (CCD) mutations are located, plays a critical
ole in Ca2 channel regulation (1). In the resting or
onactivated state of ryanodine receptor (RyR), the 2
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006, accepted January 1, 2007.omains make close contact at several sub-domains (domain
ipping). The conformational constraints imparted by the
zipped” configuration stabilize the closed state of the
hannel. Mutation in either of these domains causes weak-
ning of the interdomain interaction and partial domain
nzipping, even in resting or nonactivating conditions.
hus, diseased channels remain partially open (1).
The domain unzipping concept can also account for the
athogenesis of mutation-caused cardiomyopathies of RyR2
e.g., arrhythmogenic right ventricular cardiomyopathy type
[ARVC2] and catecholaminergic polymorphic ventricular
achycardia [CPVT]), in which more than 40 mutations
ave been identified in the corresponding regions seen in
H and CCD (2). In our recent study of the pacing-
nduced heart failure model (3), we have shown that
efective interdomain interaction destabilizes the channel
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April 24, 2007:1722–32 Redox and Ryanodine Receptor Functionating of the RyR2, causing serious consequences, such as
a2 leak, cyclic adenosine monophosphate (cAMP)-
ependent hyperphosphorylation of RyR2, and FKBP12.6
issociation from RyR2. This suggests that the weakened
nterdomain interaction is 1 of the key pathogenic mechanisms
ot only in mutation-caused cardiomyopathy (ARVC2 and
PVT) but also in heart failure. In further support of this view,
e have shown that a benzothiazepine derivative JTV519
K201) corrects domain unzipping in the diseased RyR2 and
revents the development of heart failure (3,4).
Calcium sulfate hemihydrate channels of RyR2 as well as
yR1 are known to be regulated by the redox state. For
nstance, oxidation or nitroxylation of the cysteine residues
n the RyR produces considerable changes in the channel
unction (5). We recently demonstrated that oxidative
tress-induced domain unzipping of these regulatory do-
ains, leading to Ca2 leak and that the antioxidant
daravone corrected the defectiveness of the interdomain
nteraction and thereby improved cardiac function against
he development of heart failure (6). The oxidative stress-
nduced domain unzipping and subsequent Ca2 leak were
gain corrected by JTV519 (K201) (6). These findings
urther support the notion that the defective interdomain
nteraction within RyR2 is a common source mechanism of
a2 leak leading to heart failure and fatal arrhythmia and
hat the defectiveness can be induced either by FKBP12.6
issociation from RyR2 and oxidative stress or inherently by
ingle point mutation within RyR2.
Carvedilol (CV) is a nonselective beta-blocker that also
as an antioxidant effect. Recent clinical trials have clearly
emonstrated that CV significantly improves cardiac func-
ion as well as the prognosis of patients with chronic heart
ailure (7). However, the underlying mechanism by which
V improves cardiac function remains to be elucidated. In
his study, we investigated the possibility that the defective
nterdomain interaction and resultant Ca2 leak seen in
ailing hearts can be corrected by CV-treatment, and we
ave found that this is in fact the case.
ethods
aterials. The FK506 and CV were provided by Astellas
harma Inc. (Tokyo, Japan) and Daiichi Pharmaceutical
o. Ltd. (Tokyo, Japan), respectively.
nimal preparation. In beagle dogs weighing 10 to 13 kg,
eart failure was induced by 28 days of rapid ventricular
RV) pacing at 250 beats/min (referred to as 4W-pacing)
ith an externally programmable miniature pacemaker
Medtronic Inc., Minneapolis, Minnesota), and both left
entricular (LV) pressure and 2-dimensional echocardio-
rams were measured in the conscious state, as previously
escribed (8). Carvedilol was chronically administered im-
ediately followed by the initiation of RV pacing. The care
f the animals and the protocols used were in accord with
uidelines laid down by the Animal Ethics Committee of
amaguchi University School of Medicine. Ureparation of sarcoplasmic re-
iculum vesicles. Sarcoplasmic
eticulum (SR) vesicles were pre-
ared from dog LV, as described
lsewhere (8).
a2-uptake and -leak assays.
a2-uptake and Ca2-leak as-
ays were performed as described
reviously (8).
eptides used and peptide syn-
hesis. We used a synthetic pep-
ide corresponding to residues
460-2495 of the RyR2, 2460GFC-
DHKAAMVLFLDRVYGIE-
QDFLLHLLEVGFLP2495
DPc10), that includes 1 residue
utable in CPVT, as described
reviously (3,9).
ite-directed fluorescence label-
ng of the RyR2. Specific fluores-
ence labeling of the RyR2 moiety
f the SR was performed with the
leavable hetero-bifunctional cross-
inking reagent sulfosuccinimidyl
-((2-(7-azido-4-methylcoumarin-
-acetamido) ethyl) dithio)pro-
ionate (SAED) from PIERCE
Rockford, Illinois), with DPc10
s a site-specific carrier, as described previously (3).
luorescence quenching of the MCA probe attached to
he DPc10 binding site. The zipped and unzipped states
f the interacting domains of the RyR2 were assessed by the
uorescence quench technique described previously (3,9).
he principle of the fluorescence quench assay of domain
nzipping is that a large-size quencher QSY (QSY-7,
olecular Probes, Eugene, Oregon)–bovine serum albumin
BSA) is inaccessible to the attached MCA in the zipped
tate, whereas it becomes accessible to the MCA site in the
nzipped state. The MCA fluorescence data (excitation at
68 nm, emission at 455 nm) were analyzed with the
tern-Volmer equation.
mmunoblot analysis. Immunoblot analyses for FKBP12.6,
R Ca2-adenosine triphosphate (ATP)ase, and phospho-
amban (PLB) were carried out as described elsewhere (4,8).
y employing the method of Marx et al. (10), we achieved
o-immunoprecipitation of FKBP12.6 from SR with anti-
yR2 antibody (Oncogene Research Products, San Diego,
alifornia) followed by immunoblotting with anti-FKBP12
C-19) antibody (Santa Cruz Biotechnology, Santa Cruz,
alifornia). The relative phosphorylation level of RyR was
etermined by immunoblotting with anti-phosphoRyR2
RyR2-pSer2808) that was kindly provided by Dr. Andrew
. Marks (Columbia University). Specific antibodies against
Ser16-PLB (Upstate Biotechnology, Lake Placid, New
ork) and an epitope common to all PLB forms (PLB;
Abbreviations
and Acronyms
CPVT  catecholaminergic
polymorphic ventricular
tachycardia
CV  carvedilol
DCFH-DA  2=,7=-
dichlorofluorescin diacetate
DPc10  a synthetic
peptide corresponding to
Gly2460-Pro2495 of
ryanodine receptor
LV  left ventricle/
ventricular
mBB  monobromobimane
MCA  methylcoumarin
acetate
PKA  protein kinase A
PLB  phospholamban
ROS  reactive oxygen
species
RV  rapid ventricular
RyR  ryanodine receptor
SIN-1 
3-morpholinosydnonimine
SR  sarcoplasmic
reticulumpstate Biotechnology) were also used.
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Redox and Ryanodine Receptor Function April 24, 2007:1722–32xidative stress level in RyR2. The content of free thiols
the number of reduced cysteines) in the canine RyR2 was
etermined with the monobromobimane (mBB, Calbio-
hem, San Diego, California) fluorescence technique
6,11,12). The mBB fluorescence in the RyR2 (excitation at
82 nm, emission at 482 nm), normalized by protein
bundance of RyR2, was defined as the relative content of
ree thiols in the RyR2.
In canine cardiomyocytes, a fluorescent probe, 2=,7=-
ichlorofluorescin diacetate (DCFH-DA, Molecular
robes), was used for the assessment of intracellular
eactive oxygen species (ROS) formation, as described
reviously (6,13). Fluorescence images (excitation at
90 nm and emission at 530 nm) were acquired
ith a microscope (LSM 510, Carl Zeiss, Oberkochen,
ermany).
a2 transient and cell shortening in canine cardio-
yocytes. Cell shortening and intracellular calcium were
easured as described previously (3). In brief, cardiomyo-
ytes were incubated with 1 mol/l fura-2 AM, 0.0045%
luronic F-127 (Sigma, St. Louis, Missouri) and 0.1% di-
ethyl sulfoxide for 30 min, then washed twice with N-(2-
ydroxyethyl)-piperazine-N=-2-ethanesulfonic acid (HEPES
uffer) containing (in mmol/l) sodium chloride 126,
otassium chloride 4.4, magnesium chloride 1.0, calcium
hloride 1.08, HEPES 24, glucose 11, sodium hydroxide
1, sodium dihydrogen phosphate 10, and probenecid 0.5
pH 7.4). Cells were stimulated by a field electric
timulator (IonOptix, Milton, Massachusetts) at 0.5 Hz.
dual excitation spectrofluorometer was used to record
uorescence emissions (505 nm) elicited from exciting
avelengths at 340 and 380 nm. The intracellular cal-
ium was monitored as the ratio of fluorescence of the cell
t 340 and 380 nm excitation.
tatistics. Paired t tests were performed for pre-post com-
arisons of hemodynamic data. Analysis of variance was
sed to compare data groups. When we identified a signif-
cant trend by the F test, we used Scheffé’s post hoc test to
ompare the data. For comparison of multiple measure-
ents, upon dose-dependent effect of CV on hemodynamic
arameters, repeated measures analysis was used. Data are
xpressed as means  SD. We accepted a p value 0.05 as
tatistically significant.
esults
etermination of an appropriate concentration of CV for
hronic administration. To determine the dose of CV to
e used for chronic administration, we evaluated the
oncentration-dependent effect of CV on hemodynamic
arameters in normal conscious dogs (Fig. 1A). Carvedilol
as orally administered for 3 days/each dose, starting at a
ose of 0.01 mg·kg1·day1 with various increments to 0.1
g·kg1·day1. At a dose of 0.02 mg·kg1·day1, neither nhe baseline peak dP/dt nor the isoproterenol-induced
notropic response was decreased, although the baseline
eart rate decreased significantly (by approximately 15%) in
ormal conscious dogs. We used this low-dose of CV (0.02
g·kg1·day1) for treatment of pacing-induced heart
ailure.
emodynamic data. In the CV-treated dogs with chronic
V pacing, normal systolic and diastolic functions were well
reserved, and none of these dogs developed heart failure
Table 1, Fig. 1B). These data indicate that in the CV-
reated dogs, there was no sign of heart failure after chronic
V pacing.
evels of oxidative stress are elevated in failing hearts. The
elative content of free thiols in the RyR2 (for definition, see
ethods section) was considerably reduced in the untreated
ailing hearts but was normal in CV-treated hearts (Fig. 2A),
ndicating that the oxidation of the RyR2 is in fact involved in
he oxidative stress in failing hearts and the normal level is
estored by CV-treatment. To examine whether the preventive
ffect of CV is in fact due to the inhibition of the oxidation of
he RyR2, we assessed the acute effect of CV on the oxidation
f the RyR2 induced by 3-morpholinosydnonimine (SIN-1),
hich generates the nitric oxide-related species peroxynitrite
OONO–). In agreement with our previous report (6), SIN-1
ecreased the number of free thiols of the RyR2 (i.e., oxida-
ion) (Fig. 2B). When SIN-1–was added together with CV,
he number of free thiols was significantly higher than that
ithout CV. This indicates that the inhibition of Ca2 leak by
V is mediated in fact by the prevention of RyR2 oxidation by
V. The DPc10 (30 mol/l), which was found to induce
efective interdomain interaction and subsequent Ca2 leak
3), did not change the relative content of free thiols. This
ndicates that CV reverses SIN-1–induced RyR oxidation and
hat defective interdomain interaction has little effect on the
yR oxidation. In contrast, when CV was added after wash-
ut of SIN-1, CV did not increase the number of free thiols
data not shown). This suggests that the actual effect of CV is
cavenging of the oxidant OONO rather than serving as a
hiol-reducing agent.
ffects of CV on SR Ca2-leak and defective FKBP12.6-
yR2 interaction in failing hearts. Addition of 0.3
mol/l thapsigargin to normal SR vesicles produced no
etectable spontaneous Ca2 leak, whereas addition of 30
mol/l FK506 together with 0.3 mol/l thapsigargin pro-
uced a pronounced leak (Fig. 3A). In contrast, in the
ailing SR vesicles from 4W-paced/CV-untreated hearts,
he addition of thapsigargin alone produced a prominent
a2 leak, but the addition of FK506 produced no further
ncrease (Fig. 3A). Importantly, neither the FK506-induced
a2 leak in normal SR nor Ca2 leak in failing SR was
nhibited by acute addition of CV, suggesting that CV has
o direct effect on channel stabilization. In the SR vesicles
rom 4W-paced/CV-treated hearts, spontaneous Ca2 leak
as not observed, and FK506 increased Ca2 leak as in the
ormal SR (Fig. 3A).
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April 24, 2007:1722–32 Redox and Ryanodine Receptor FunctionIn the failing SR vesicles, the RyR2 was protein kinase
(PKA)-hyperphosphorylated, but CV treatment re-
uced the RyR2 phosphorylation to a level seen in the
ormal hearts (Fig. 3B). The amount of RyR2-associated
Figure 1 Hemodynamics and Echocardiograms
(A) Acute concentration-dependent effect of carvedilol (CV) on resting and isoproteren
intravenously) was used to produce inotropic response. Data represent mean  SD
tricular (LV) end-diastolic and -systolic diameters were each smaller in the CV-treated d
ventricular peak-systolic pressure; dP/dt  peak () dP/dt of LV pressure. *p 
emodynamic Data
Table 1 Hemodynamic Data
HR
(beats/min)
LVPSP
(mm Hg)
LVEDP
(mm Hg)
Carvedilol-untreated (n  7)
Prepacing 134 16 125 10 7.7 2.1
4W-pacing 126 13 119 15* 31.7 3.8*
Carvedilol-treated (n  7)
Prepacing 129 24 129 12 9.2 4.3
4W-pacing 123 12 119 16 16.3 4.1*†
ata represent mean  SD. *p  0.01 versus prepacing; †p  0.01 versus carvedilol-untreated.
()dP/dt peakdP/dt of left ventricular pressure; HR heart rate; LVEDD left ventricular en
iameter; LVFS  left ventricular fractional shortening: (LVEDDLVESD)/LVEDD  100; LVPSP  left v
sovolumic relaxation period; W  week.KBP12.6 was decreased by 4W-pacing, but FKBP12.6
issociation was prevented by CV treatment (Fig. 3C).
cute addition of CV (100 mol/l) to failing SR did not
hange the level of phosphorylation at RyR2-pSer2808
ulated hemodynamic in normal conscious dogs. Isoproterenol (0.80 g·kg-1·min1
ed from 4 dogs. (B) Representative M-mode echocardiograms. Note that left ven-
n in the CV-untreated (–) dog (both 4-week paced). HR  heart rate; LVPSP  left
; **p  0.01 versus CV ().
)dP/dt
Hg/s)
Tau
(ms)
LVEDD
(mm)
LVESD
(mm)
LVFS
(%)
 646 19.3 2.0 32.0 1.5 22.2 3.0 33.4 8.1
 220* 37.5 7.0* 39.8 1.5* 34.8 1.9* 12.7 2.7*
 876 18.8 4.9 32.0 2.5 21.7 1.9 31.7 5.9
 138*†‡ 27.0 1.5*† 36.0 1.7*† 28.4 2.6*† 20.0 4.0*†
.05.
olic diameter; LVEDP left-ventricular end-diastolic pressure; LVESD left ventricular end-systolicol-stim
obtain
og tha
0.05(
(mm
3,148
1,378
2,988
1,643
‡p  0
d-diastentricular peak-systolic pressure; Tau  time constant of left ventricular pressure decay during
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Redox and Ryanodine Receptor Function April 24, 2007:1722–32nd the amount of RyR2-bound FKBP12.6 (Fig. 3C). These
esults indicate that CV prevents PKA-hyperphosporylation
f RyR2 and FKBP 12.6 dissociation during the 4W-pacing
ut it has no acute and direct effect on the intrinsic
ctivities of PKA-phosphorylation and FKBP12.6 bind-
Figure 2 Redox State in RyR2
(A) Monobromobimane (mBB) fluorescence intensity of the ryanodine receptor (Ry
mol/l 3-morpholinosydnonimine (SIN-1). The relative content of free thiols in the
dance of RyR2 and then expressed as a percentage of that in normal sarcoplasmi
induced decrease in mBB fluorescence intensity of the RyR2. (C) Acute effect of C
absence of SIN-1 (100 mol/l) and/or DPc10 (a synthetic peptide correspondingng of RyR2. 1ffects of oxidative stress on Ca2 leak, interdomain
nteraction within RyR2, and FKBP12.6-RyR2 interac-
ion. To assess the direct antioxidant effect of CV on Ca2
eak, we investigated the inhibitory effect of CV on SIN-1-
nduced Ca2 leak in normal SR. As shown in Figure 4A,
rresponding to the content of free thiols) in the presence or absence of 100
was obtained as the ratio of fluorescence intensity of the mBB to protein abun-
ulum. (B) Acute concentration effect of carvedilol (CV) on SIN-1 (100 mol/l)–
mol/l) on the mBB fluorescence intensity of the RyR2 in the presence or
460-Pro2495 of RyR) (30 mol/l).R)2 (co
RyR2
c retic
V (100
to Gly200 mol/l SIN-1 increased the Ca2 leak, and this Ca2
l
t
w
m
i
m
r
p
c
c
t
i
i
w
e
a
1727JACC Vol. 49, No. 16, 2007 Mochizuki et al.
April 24, 2007:1722–32 Redox and Ryanodine Receptor Functioneak was completely inhibited by 100 mol/l CV. However,
his effect was completely abolished when 30 mol/l DPc10
as added to induce Ca2 leak through defective interdo-
ain interaction within the RyR2 (3).
To monitor the zipped and unzipped states of the
nteracting domains of the RyR2, we used QSY-BSA as a
acromolecular quencher (Figure 4B). As in the case of our
ecent study with DPc10 (3), the slope of the Stern-Volmer
Figure 3 Ca2 Leak, Ser2808-Phosphorylation Level in RyR2, an
(A) Representative time courses of Ca2 uptake and the ensuing Ca2 leak from
dilol (CV) (left). Summarized data of Ca2 leak in normal, CV-untreated, and CV-tre
tion level of RyR2. (C) The amount of RyR2-bound FKBP12.6. To see the direct ac
FKBP 12.6 in failing SR vesicles, the SR vesicles were mixed with CV (100 mol/
ting. 4W-pacing  pacing at 250 beats/min for 4 weeks; ATP  adenosine triphoslot, which represents KQ (the Stern-Volmer quenching ponstant: a measure of the extent of domain unzipping) was
onsiderably increased by SIN-1 (100 mol/l), indicating
hat SIN-1 in fact induced a sizable opening between the
nteracting domains (Fig. 4B, top panel). The SIN-1–
nduced increase in the extent of fluorescence quenching
as almost completely reversed by 100 mol/l CV. How-
ver, this inhibitory effect of CV was again completely
bolished in the presence of 30 mol/l DPc10 (Fig. 4B, top
BP12.6
icles in the presence or absence of 30 mol/l FK506 and/or 100 mol/l carve-
sarcoplasmic reticulum (SR) vesicles (right). (B) Protein kinase A phosphoryla-
ect of CV on phosphorylation level of RyR2-pSer2808 or amount of RyR2-bound
0 min and then centrifuged, followed by immunoprecipitation and Western blot-
; other abbreviations as in Figure 2.d FK
SR ves
ated
ute eff
l) for 3
phateanel). These results suggest that the inhibition of Ca2 leak
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Redox and Ryanodine Receptor Function April 24, 2007:1722–32y CV is mediated by its reversal of the domain unzipping that
as been produced by the SIN-1 oxidation. The extent of
uorescence quenching (KQ) in failing SR vesicles was larger
han for the normal SR. However, in the SR vesicles from
W-paced/CV-treated hearts, KQ values were comparable to
he values of the normal SR (Fig. 4B, bottom panel). These
esults suggest that domain unzipping has already taken place
n failing SR vesicles (caused partly by PKA-phosphorylation
ediated FKBP12.6 dissociation and oxidative stress) and that
V treatment restores the normal zipped state, thereby pre-
enting Ca2 leak. As shown in Figure 4C, both RyR2-
Ser2808 and RyR2-bound FKBP12.6 were not altered by
IN-1, regardless of the presence of CV or DPc10.
ffects of CV on the amount of SR Ca2-ATPase, the rate
f Ca2 uptake, and the ratio of Ser16-phosphorylated PLB
nd total PLB in failing hearts. After RV pacing for 4
Figure 4 Ca2 Leak and Interdomain Interaction Within RyR2
(A, top) Representative time courses of Ca2 uptake and Ca2 leak from SR vesi
marized data of Ca2 leak (bottom). (B) Stern-Volmer plots of the fluorescence qu
SIN-1 (100 mol/l) in the presence or absence of CV (100 mol/l) or CV (100 m
QSY-BSA fluorescence quenching data of normal, failing (CV-untreated/paced), and
of RyR2-pSer2808 (top) or amount of RyR2-bound FKBP12.6 (bottom), in the prese
vesicles were mixed with CV or DPc10 for 30 min and then centrifuged, followed beeks, both the SR Ca2 uptake activity and the amount of cR Ca2-ATPase were reduced, and these changes were
ot observed in the CV-treated group (Figs. 5A and 5B).
he levels of Ser16-phosphorylated PLB (p-PLB) and total
LB (t-PLB) among these groups of SR vesicles are
ompared in Figure 5C (top figure: gel picture; bottom
gure: the calculated values of relative phosphorylation).
here was no difference in the level of total PLB among the
groups, but there was a significant decrease in the basal
evel of phosphorylated PLB in the failing SR vesicles. In
R vesicles from 4W-paced/ CV-treated hearts, the level of
hosphorylated PLB was restored back toward a normal
evel.
ffects of CV on Ca2 transient and cell shortening in
ormal and failing cardiomyocytes. We further assessed
hether the adverse effects of oxidative stress on SR Ca2
elease function and its reversal by CV seen in SR vesicles
presence of SIN-1 (100 mol/l), CV (100 mol/l), or DPc10 (30 mol/l). Sum-
ng data with QSY-bovine serum albumin (BSA). The top panel shows the effect of
lus DPc10 (30 mol/l) in normal SR. Bottom panel shows Stern-Volmer plots of
eated/paced groups. (C) Effect of SIN-1 (100 mol/l) on phosphorylation level
f CV (100 mol/l) or DPc10 (30 mol/l). Before immunoprecipitation of RyR, SR
tern blotting. Abbreviations as in Figures 2 and 3.cles in
enchi
ol/l) p
CV-tr
nce o
y Wesan be also seen in canine cardiomyocytes. First, we deter-
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April 24, 2007:1722–32 Redox and Ryanodine Receptor Functionined the dose of CV that is sufficient for the antioxidant
ffect but not for the beta-blocking (inverse agonism) effect.
igure 6A shows the concentration-dependent effect of CV
n cell shortening of normal and failing cardiomyocytes.
cute addition of CV (30 nmol/l) had no appreciable
ffect on the cell shortening in both cardiomyocytes. Like-
ise, CV (30 nmol/l) had no appreciable effect on Ca2
ransients even after stimulation by forskolin (Fig. 6B). In
ontrast, in failing cardiomyocytes, incubation with CV (30
Figure 5 SR Ca2-ATPase, Ca2 Uptake, and Phospholamban
(A) Representative Western blot of sarcoplasmic reticulum (SR) Ca2-ATPase (top
rate of Ca2 uptake. (C) Representative Western blot of Ser16-phosphorylated pho
of the Western blot (bottom panel). The p-PLB values (sum of pentamer and mono
tamer and monomer, in arbitrary units). Data are presented as means  SD. Abbrmol/l) for 12 h resulted in a significant if not complete wmprovement of both the Ca2 transient and cell shortening
t baseline and in the presence of forskolin (Fig. 6C).
owever, when DPc10 was incorporated into failing cardi-
myocytes by protein delivery kit (Bioporter, Gene Therapy
ystems, Inc., San Diego, California), the beneficial effects
f CV (30 nmol/l) were completely abolished (Fig. 6C).
his finding suggests that the beneficial effect of CV on
ailing cardiomyocyte function is mediated through amelio-
ation of defective interdomain interaction in the RyR2,
) and the densitometric analysis of the Western blot (bottom panel). (B) The
mban (p-PLB) and total PLB (t-PLB) (top panel) and the densitometric analysis
in arbitrary units) were normalized with respect to the t-PLB values (sum of pen-
ns as in Figure 3.panel
sphola
mer,
eviatiohich is induced by an inhibition of oxidative stress within
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Redox and Ryanodine Receptor Function April 24, 2007:1722–32yR2. In contrast to the aforementioned effect of CV (30
mol/l), metoprolol (100 nmol/l), at a dose that did not
cutely change baseline cell shortening in normal cardiomy-
cytes but decreased cell shortening after addition of iso-
roterenol (50 nmol/l) (28  5%; n  6, p  0.01 vs.
aseline, similar to the decrease by CV [30 nmol/l]: 29 
%; n  6, p  0.01 vs. baseline), had no effect on both cell
hortening and Ca2 transient in failing cardiomyocytes.
able 2 summarizes the cell shortening and Ca2 transient
ata in normal and failing cardiomyocytes. Figure 6D shows
he estimated SR Ca2 content by caffeine application. In
ailing cardiomyocytes, SR Ca2 content was reduced,
hereas incubation with CV for 12 h increased the SR
a2 content. However, incorporation of DPc10 into the
ailing cardiomyocyte eliminated the increase in SR Ca2
Figure 6 Cell Shortening and the Corresponding Ca2 Transien
(A) Dose-dependent effect of CV on cell shortening in normal and failing (4W-pace
Ca2 transient in normal (B) and failing cardiomyocytes (C), in the presence of CV
tent by caffeine (20 mmol/l) application in the presence of CV (30 nmol/l, incubat
fluorescence images in normal and failing cardiomyocytes in presence of CV (30 n
the DCFH-DA fluorescence signal indicated as green in failing cardiomyocytes. Cel
Fluor 633 conjugate; Molecular Probes). Abbreviations as in Figure 3.ontent by CV. bFigure 6E shows the fluorescence images after application
f the fluorescent probe of intracellular ROS, DCFH-DA
1 mol/l), into the normal and failing cardiomyocytes. In
ailing cardiomyocytes, the fluorescence intensity was in-
reased to a high level, but a normal level of fluorescence
ntensity was restored by application of 30 nmol/l CV (Fig.
C). Introduction of DPc10 into the failing cardiomyocyte
ad no appreciable effect on intracellular ROS. These
ndings indicate that the ROS level is increased in failing
ardiomyocytes, which can indeed be reversed by incubation
f CV, and that domain unzipping of the regulatory domain
n RyR2 does not increase ROS per se.
iscussion
he most important new aspect of this study is that the
ardiomyocytes
iomyocytes. (B and C) Effect of forskolin (500 nmol/l) on cell shortening and
mol/l, incubated for 12 h) or DPc10-incorporation. (D) Estimated SR Ca2 con-
12 h) or DPc10-incorporation. (E) 2=,7=-dichlorofluorescin diacetate (DCFH-DA)
incubated for 12 h) or DPc10-incorporation. Confocal microscopy clearly detects
ce membrane was fluorescently labeled as red by wheat germ agglutinin (Alexat in C
d) card
(30 n
ed for
mol/l,
l surfaeneficial effects of CV on the in vivo cardiac function seem
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April 24, 2007:1722–32 Redox and Ryanodine Receptor Functiono be attributable to the restoration of defective inter-
omain interaction within RyR2, either by preventing PKA
yperphosphorylation-induced dissociation of FKBP12.6
rom RyR2 or by reducing the oxidative stress level within
yR2 or by both. In this study, we demonstrated that
ncubation of failing cardiomyocytes with low-dose CV (30
mol/l; for 12 h), which is not sufficiently high to inhibit
ell shortening acutely, significantly improved cardiomyo-
yte function (i.e., increase in cell shortening and peak of
a2 transient), concurrent with a reduction of ROS level
n failing cardiomyocytes. This finding strongly suggests
hat the antioxidant effect of CV is enough to improve
ardiomyocyte function as a chronic effect, even without
xerting a beta-blocking effect.
Importantly, this beneficial effect of low-dose CV on
ardiomyocyte function is completely abolished when do-
ain unzipping is introduced by incorporating DPc10, a
ynthetic peptide corresponding to Gly2460-Pro2495 of RyR
one of the mutable domains in CPVT), into failing
ardiomyocytes. As shown in our previous study (3), DPc10
as found to induce domain unzipping and Ca2 leak
ithout causing any changes in the level of PKA phosphor-
lation within RyR2 and in the amount of the RyR2-bound
KBP12.6. These results suggest that the beneficial effects
f low-dose of CV (30 nmol/l) on failing cardiomyocyte
unction is solely attributable to the restoration of defective
nterdomain interaction (i.e., from unzipped state to a
ipped state) by reducing the oxidative stress level within the
yR2. This notion is supported by the following findings.
he treatment of the SR isolated from normal hearts with
ONO-donor SIN-1 resulted in a considerable reduction
n the content of reactive thiols in the RyR2 moiety. In
ailing SR vesicles, the content of reactive thiols was
onsiderably reduced; however, the thiol content in the SR
rom the CV-administered hearts was essentially identical
o that of the normal control even after RV pacing for 4
eeks. Moreover, the SIN-1–induced oxidative stress
ithin the RyR2 of normal SR resulted in an increased
xtent of domain unzipping (defective interdomain interac-
ion), but CV prevented the defective interdomain interac-
n Vivo Cell Shortening and Ca2 Transient in Normal and Failing C
Table 2 In Vivo Cell Shortening and Ca2 Transient in Normal a
Cell Shortening
(% Decrease From Baseline)
()
Forskolin
(500 nmol/l)
Normal (n  30)
Untreated 8.7 1.2 13.2 1.9
Carvedilol (30 nmol/l) 8.4 1.3 13.5 1.7
Heart failure (n  30)
Untreated 1.7 0.5 2.1 0.5
Carvedilol (30 nmol/l) 4.9 0.9* 8.5 1.7*†
Carvedilol (30 nmol/l)  DPc10 1.6 0.7§ 1.9 0.8§
Metoprolol (100 nmol/l) (n  20) 1.9 0.3§ 2.4 0.8§
p  0.01 versus untreated, †p  0.01 versus forskolin (), ‡p  0.05, §p  0.01 versus carvedion from occurring. In addition, the SR Ca2 leak was mncreased by SIN-1–mediated oxidation of normal SR, but
gain it was reversed by CV. However, if DPc10 was used
o force the domains to unzip, CV was without effect (3).
The improvement of failing cardiomyocyte function by
V might partly be attributable to the improvement of
eta-adrenergic signaling by its beta-blocking effect (e.g.,
ncreases in SR Ca2-ATP activity, myofibrillar ATPase
ctivity, creatine kinase activity) (14). Also, the fact that
hronic administration of CV to failing hearts suppressed
er 2808 RyR phosphorylation suggests that the reduced
xidation of RyR might partly be attributable to the
ndirect beta-blocking effect of CV rather than antioxi-
ant effect. However, the fact that an equivalent low-dose
f metoprolol, exerting a similar degree of beta-blocking
ction as CV, had no effect on improvement of failing
ardiomyocyte function suggests that the antioxidant
ffect of CV plays a predominant role in improving
ailing cardiomyocyte function.
In this study, we used the dose of CV at which heart rate
as decreased by 10% to 15%, but LV contractility was
nchanged. This dose might correspond with the initial trial
ose of CV used for the treatment of human heart failure.
ome patients do not tolerate the incremental dosage of
eta-blocker. On the basis of the present findings, a low
ose of CV, which has antioxidant effects but not apprecia-
le beta-blocking effects, might be enough to improve
utcome of patients with heart failure. Indeed, in the
ucha trial (15), administration of very low doses of CV (5
g/day) to Japanese patients with chronic heart failure
ecreased the risk of cardiovascular events by 71%.
Chronic administration of CV improved the Ca2 uptake
unction, SERCA2a expression, and PLB phosphorylation.
bviously, these effects lead to increased SR Ca2 load and,
n turn, increased Ca2 release from RyR2, leading to
nhanced LV contractility. Phosphorylation of PLB at
er16 by PKA and at Thr17 by CAMKII might also
ontribute to improvement of LV function in failing hearts.
In conclusion, administration of CV during RV pacing of
he canine heart prevented the development of heart failure,
y correcting several problems occurring in the RyR2
myocytes
ailing Cardiomyocytes
Peak of Ca2 Transient
(% Increase From Baseline)
Time From Peak to 80% Decline
(102 s)
()
Forskolin
(500 nmol/l) ()
Forskolin
(500 nmol/l)
0.5 4.6 54.7 4.7 83.3 23.5 61.4 16.6
9.9 5.1 53.5 11.1 85.3 18.2 64.6 14.6
4.7 3.7 16.3 2.8 129.1 17.5 115.3 29.8
5.6 3.2* 40.0 8.7*† 104.8 18.8‡ 74.5 15.4*†
5.1 2.7§ 16.4 2.7§ 123.9 25.8 114.0 19.4§
5.4 2.9§ 16.9 3.1§ 123.5 10.9 113.4 13.2§
nmol/l.ardio
nd F
3
2
1
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Redox and Ryanodine Receptor Function April 24, 2007:1722–32nteraction of the regulatory domains in the RyR2, partial
issociation of FKBP12.6, PKA hyperphosphorylation, and
a2 leak. Oxidation of the cysteine residues of the RyR2
ith SIN-1 destabilized the interdomain interaction mim-
cking the situation in the failing SR, but upon treatment of
he SR with CV the normal mode of interdomain interac-
ion was restored, with concurrent inhibition of Ca2 leak.
he present study provides the molecular basis as to why
V is effective for improving the prognosis of patients with
hronic heart failure.
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